AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6496995 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 30
Study 6496995 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 30
Study 6496995 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine and Intravenous morphine
Number of subjects: 30
Study 31614596 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital support system for homework delivery via the Internet
Number of subjects: 0
Study 31614596 — intervention group
Group type: COMPARATOR
Intervention: Traditional homework condition
Number of subjects: 0
Study 31614596 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (Digital support system and Traditional homework)
Number of subjects: 0
Study 30152782 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology Taping muscle application (KT group)
Number of subjects: 50
Study 30152782 — intervention group
Group type: COMPARATOR
Intervention: Placebo application of adhesive tape (placebo group)
Number of subjects: 50
Study 26739116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high‐intensity exercise (IHE)
Number of subjects: 10
Study 26739116 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 10
Study 24487957 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity laser therapy (HILT) + exercise
Number of subjects: 53
Study 24487957 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) + exercise
Number of subjects: 53
Study 24487957 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser + exercise (PL + EX)
Number of subjects: 53
Study 22204948 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia program (Play Nicely) - 40-min lecture
Number of subjects: 19
Study 22204948 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19
Study 20683071 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine nasal spray
Number of subjects: 206
Study 20683071 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 206
Study 22065170 — intervention group
Group type: EXPERIMENTAL
Intervention: Tovaxin (autologous T-cell immunotherapy)
Number of subjects: 150
Study 22065170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 15976241 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 54
Study 15976241 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 54
Study 12850395 — intervention group
Group type: EXPERIMENTAL
Intervention: lercanidipine 10 to 20 mg
Number of subjects: 60
Study 12850395 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine GITS 30 to 60 mg
Number of subjects: 60
Study 10593371 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg of ganirelix administered subcutaneously
Number of subjects: 19
Study 10593371 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg of ganirelix administered intravenously
Number of subjects: 19
Study 8915229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine-atropine echocardiography
Number of subjects: 102
Study 8915229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole echocardiography
Number of subjects: 102
Study 8915229 — intervention group
Group type: COMPARATOR
Intervention: Exercise stress test
Number of subjects: 102
Study 8915229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole and dobutamine-atropine echocardiography
Number of subjects: 102
Study 8915229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole infusion
Number of subjects: 102
Study 1845584 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Advice
Number of subjects: 0
Study 1845584 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Counselling
Number of subjects: 0
Study 1845584 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Counselling
Number of subjects: 0
Study 1845584 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 6809161 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine chewing-gum
Number of subjects: 58
Study 6809161 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mg nicotine, unbuffered)
Number of subjects: 58
Study 29195739 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopic gastrectomy
Number of subjects: 419
Study 29195739 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopic gastrectomy
Number of subjects: 419
Study 28931384 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based tool for parents (monthly emails with links to an age-appropriate website)
Number of subjects: 718
Study 28931384 — intervention group
Group type: COMPARATOR
Intervention: Ordinary care from child health centres
Number of subjects: 718
Study 26037730 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for 8 weeks
Number of subjects: 39
Study 26037730 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (no acupuncture treatment)
Number of subjects: 39
Study 23833851 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg) added to bupivacaine (0.5%) - fentanyl (50 microg)
Number of subjects: 72
Study 23833851 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (0.5%) - fentanyl (50 microg) with saline normal (control)
Number of subjects: 72
Study 19961932 — intervention group
Group type: COMPARATOR
Intervention: Proguanil alone
Number of subjects: 15
Study 19961932 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil with efavirenz (400mg daily for 11 days)
Number of subjects: 15
Study 19961932 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil with efavirenz
Number of subjects: 15
Study 19213336 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuntai Capsule (KTC) 4 capsules twice a day for 1 year
Number of subjects: 104
Study 19213336 — intervention group
Group type: COMPARATOR
Intervention: Premarin 0.45 mg per day (with 2 mg medroxyprogesterone for Ue) for 1 year
Number of subjects: 104
Study 19213336 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuntai Capsule (KTC)
Number of subjects: 104
Study 16903931 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 778
Study 16903931 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 778
Study 16903931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 778
Study 12533086 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial serum neuron-specific enolase (NSE) level
Number of subjects: 81
Study 10812283 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily buprenorphine administration (8 mg)
Number of subjects: 60
Study 10812283 — intervention group
Group type: COMPARATOR
Intervention: Thrice-weekly buprenorphine administration (16 mg on Mondays and Wednesdays, 24 mg on Fridays)
Number of subjects: 60
Study 8652330 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece breathing in supine position
Number of subjects: 13
Study 8652330 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask breathing in supine position
Number of subjects: 13
Study 2052294 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mm small incision with 6.5-mm silicone optic PC IOL
Number of subjects: 130
Study 2052294 — intervention group
Group type: COMPARATOR
Intervention: 6.5-mm conventional incision with 6.0-mm PMMA optic PC IOL
Number of subjects: 130
Study 6809024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen 200 mg 8 hourly
Number of subjects: 8
Study 6809024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29384321 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin (8 mg once daily for 8 weeks)
Number of subjects: 44
Study 26922656 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8529 40 mg
Number of subjects: 0
Study 26922656 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg
Number of subjects: 0
Study 26922656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24126097 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (25-100 mg/day) for 9 weeks or fewer
Number of subjects: 1520
Study 24126097 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 1520
Study 24126097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1520
Study 22889038 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-day class scheduled at 8:30 a.m., 10:00 a.m., or 12:30 p.m. (academic constraint conditions)
Number of subjects: 230
Study 22889038 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-day class scheduled at 8:30 a.m. or 12:30 p.m. (academic constraint conditions)
Number of subjects: 230
Study 22889038 — intervention group
Group type: EXPERIMENTAL
Intervention: 8:30 a.m. exam condition
Number of subjects: 230
Study 22889038 — intervention group
Group type: COMPARATOR
Intervention: No next-day class (control condition)
Number of subjects: 230
Study 21076372 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis (900 mg once daily for 200 days)
Number of subjects: 318
Study 21076372 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis (900 mg once daily for 100 days)
Number of subjects: 318
Study 18179317 — intervention group
Group type: EXPERIMENTAL
Intervention: Effort to modulate the use of racial information
Number of subjects: 0
Study 18179317 — intervention group
Group type: COMPARATOR
Intervention: Less effort to modulate the use of racial information
Number of subjects: 0
Study 16120821 — intervention group
Group type: COMPARATOR
Intervention: 32 mg/d candesartan
Number of subjects: 32
Study 16120821 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 mg/d candesartan
Number of subjects: 32
Study 11865366 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intravenous antithrombin III
Number of subjects: 36
Study 11865366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraabdominal donor serum
Number of subjects: 36
Study 11865366 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 36
Study 10599402 — intervention group
Group type: EXPERIMENTAL
Intervention: Normovolemic haemodilution with crystalloid solutions until a hematocrit value of 21%
Number of subjects: 60
Study 10599402 — intervention group
Group type: COMPARATOR
Intervention: Control group with target transfusion hematocrit value of >= 28%
Number of subjects: 60
Study 7783015 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐ring attachment
Number of subjects: 17
Study 7783015 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnet attachment
Number of subjects: 17
Study 7783015 — intervention group
Group type: COMPARATOR
Intervention: Conventional denture
Number of subjects: 17
Study 2396264 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 41
Study 2396264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 492050 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mg/kg)
Number of subjects: 10
Study 492050 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (0.2 mg/kg)
Number of subjects: 10
Study 492050 — intervention group
Group type: COMPARATOR
Intervention: Orciprenaline (7 micrograms/kg)
Number of subjects: 10
Study 31779696 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2g/day for 26 weeks
Number of subjects: 162
Study 31779696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 27697423 — intervention group
Group type: EXPERIMENTAL
Intervention: Sticker prompts affixed to refuse bins in treatment group
Number of subjects: 33684
Study 27697423 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sticker prompts)
Number of subjects: 33684
Study 25889304 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 20
Study 25889304 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 20
Study 23595232 — intervention group
Group type: EXPERIMENTAL
Intervention: Olecranon memory connector (OMC)
Number of subjects: 40
Study 23595232 — intervention group
Group type: COMPARATOR
Intervention: Locking plates
Number of subjects: 40
Study 21359979 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine injection (1/100,000) in the control group
Number of subjects: 113
Study 21359979 — intervention group
Group type: EXPERIMENTAL
Intervention: No epinephrine injection in the intervention group
Number of subjects: 113
Study 21359979 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study 19583649 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Technique (PMRT) performed for 63 sessions over two months
Number of subjects: 66
Study 19583649 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study 18232619 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy for Appropriate Medication Use Scale (SEAMS)
Number of subjects: 436
Study 15533488 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (15% fat or less) with supplements (vitamin E and selenium)
Number of subjects: 48
Study 15533488 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (15% fat or less) without supplements
Number of subjects: 48
Study 15533488 — intervention group
Group type: COMPARATOR
Intervention: Supplements alone (vitamin E and selenium)
Number of subjects: 48
Study 15533488 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 11440068 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped intervention using peer educators and a health professional
Number of subjects: 160
Study 11440068 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 160
Study 9659838 — intervention group
Group type: EXPERIMENTAL
Intervention: E + C (ephedrine 20 mg and caffeine 200 mg)
Number of subjects: 136
Study 9659838 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 136
Study 8719299 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy for 3 months
Number of subjects: 8
Study 8719299 — intervention group
Group type: COMPARATOR
Intervention: GHRH (1 microgram/kg iv) alone
Number of subjects: 8
Study 8719299 — intervention group
Group type: COMPARATOR
Intervention: GHRH combined with pyridostigmine (PD, 120 mg po)
Number of subjects: 8
Study 8719299 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal NE levels
Number of subjects: 8
Study 8719299 — intervention group
Group type: EXPERIMENTAL
Intervention: PD administration
Number of subjects: 8
Study 2672909 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 12
Study 2672909 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 12
Study 145819 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring-loaded clip
Number of subjects: 300
Study 145819 — intervention group
Group type: COMPARATOR
Intervention: Electrocoagulation
Number of subjects: 300
Study 31279972 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + VOM ethanol infusion
Number of subjects: 405
Study 31279972 — intervention group
Group type: COMPARATOR
Intervention: PVI alone
Number of subjects: 405
Study 28067195 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) + iron
Number of subjects: 100
Study 28067195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26031921 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every 4 weeks up to 7 years
Number of subjects: 437
Study 22350036 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthan-based 1.5% chlorhexidine (CHX) gel (Xan-CHX)
Number of subjects: 0
Study 22350036 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study 20924986 — intervention group
Group type: EXPERIMENTAL
Intervention: High goal-state access cost (mouse movement and a 2.5-s delay)
Number of subjects: 36
Study 20924986 — intervention group
Group type: EXPERIMENTAL
Intervention: Low goal-state access cost
Number of subjects: 36
Study 20924986 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium goal-state access cost
Number of subjects: 36
Study 20924986 — intervention group
Group type: EXPERIMENTAL
Intervention: Low access cost
Number of subjects: 36
Study 19116968 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium EDTA administration through single needle mesotherapy and 15 minutes of pulsed-mode 1 MHz-ultrasound
Number of subjects: 80
Study 19116968 — intervention group
Group type: COMPARATOR
Intervention: Control group (no disodium EDTA treatment)
Number of subjects: 80
Study 19116968 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium EDTA administration
Number of subjects: 80
Study 16924529 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity deep water running with vest
Number of subjects: 29
Study 16924529 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 12692182 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (500 mg day-1 for 8 weeks)
Number of subjects: 0
Study 12692182 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented subjects
Number of subjects: 0
Study 12692182 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 0
Study 10502166 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin mouthwash
Number of subjects: 59
Study 10502166 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 59
Study 10502166 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study 8709660 — intervention group
Group type: EXPERIMENTAL
Intervention: Insured patients
Number of subjects: 1182
Study 8709660 — intervention group
Group type: COMPARATOR
Intervention: Uninsured patients
Number of subjects: 1182
Study 8709660 — intervention group
Group type: EXPERIMENTAL
Intervention: Discretionary services for insured patients
Number of subjects: 1182
Study 8709660 — intervention group
Group type: COMPARATOR
Intervention: Discretionary services for uninsured patients
Number of subjects: 1182
Study 8709660 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondiscretionary services for insured patients
Number of subjects: 1182
Study 8709660 — intervention group
Group type: COMPARATOR
Intervention: Nondiscretionary services for uninsured patients
Number of subjects: 1182
Study 2058825 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane‐N2O‐O2 (1.3 MAC)
Number of subjects: 24
Study 2058825 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA) with propofol and alfentanil (ED95)
Number of subjects: 24
Study 2058825 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (25 mg i.v.) given to 5 patients from K1
Number of subjects: 24
Study 2058825 — intervention group
Group type: EXPERIMENTAL
Intervention: Shivering observed in K1
Number of subjects: 24
Study 6641236 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 4082090 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 50 mg/day
Number of subjects: 15
Study 4082090 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 324 mg/day
Number of subjects: 15
Study 4082090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30500136 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based hypoallergenic ointment (Doctor Rogers RESTORE® Healing Balm)
Number of subjects: 10
Study 30500136 — intervention group
Group type: COMPARATOR
Intervention: Petroleum-based lanolin-containing ointment (Aquaphor® Healing Ointment)
Number of subjects: 10
Study 27354070 — intervention group
Group type: EXPERIMENTAL
Intervention: NEAT programme
Number of subjects: 16
Study 27354070 — intervention group
Group type: EXPERIMENTAL
Intervention: ATLAS programme
Number of subjects: 16
Study 27354070 — intervention group
Group type: EXPERIMENTAL
Intervention: NEAT and ATLAS programmes
Number of subjects: 16
Study 27354070 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 16
Study 23912563 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily
Number of subjects: 0
Study 23912563 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily
Number of subjects: 0
Study 23912563 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban in infants and preschool children (body weight <40 kg)
Number of subjects: 0
Study 23912563 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban in children with body weight between 40 and 70 kg
Number of subjects: 0
Study 23912563 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban in adolescents of >70 kg body weight
Number of subjects: 0
Study 22424576 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Peripheral Iridotomy (LPI)
Number of subjects: 230
Study 22424576 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 230
Study 20605007 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional social support (fss) measured with the MOS Social Support Survey
Number of subjects: 132
Study 20605007 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional social support (fss)
Number of subjects: 132
Study 20605007 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived practical social support
Number of subjects: 132
Study 18779278 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meals enriched in monounsaturated fatty acids (MUFAs)
Number of subjects: 0
Study 18779278 — intervention group
Group type: COMPARATOR
Intervention: High-fat meals enriched in saturated fatty acids (SFAs)
Number of subjects: 0
Study 15773645 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection
Number of subjects: 93
Study 15773645 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of local anaesthetic and steroid
Number of subjects: 93
Study 12913719 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg selenium daily orally for 1 month
Number of subjects: 51
Study 12913719 — intervention group
Group type: COMPARATOR
Intervention: Control group (no selenium supplementation)
Number of subjects: 51
Study 10498759 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) capsules (2 g b.d.; containing 1.4 g eicosapentaenoic acid and 1.0 g docosahexaenoic acid per day)
Number of subjects: 49